WELCOME TO BIOVEN
The Bioven Group's main focus is on the treatment of cancer. Bioven has a dual strategy of developing its own IP as well as in-licensing compounds to be developed through late-stage clinical trials prior to out-licensing to major healthcare or specialty pharma companies.
Meet us at the American Society of Clinical Oncologists (ASCO) annual meeting 2013 in Chicago, Illinois, 31 May – 4 June 2013
To arrange a meeting, please contact info@bioven.com
NEWS
1st International Congress on Controversies in Personalized Oncology (CONPO).
Bioven (Europe) Ltd, had abstract presentation at the 1st International Congress on Controversies in Personalised Oncology (CONPO) in Barcelona, Spain on the 7-10th March 2013.*
___________________________________________________________________
31st Annual JP Morgan Healthcare Conference
5th January 2013
London, UK - Bioven (Europe) Limited, the late-stage biopharmaceutical company focused on cancer, is pleased to announce that it will be presenting at the 31st Annual JP Morgan Healthcare Conference, which takes place in San Francisco on 7-10 January 2013. Read More
CONTACT US
Physician Enquiries
Corporate Enquiries
Patient
Enquiries
Enquiries
Media
Enquiries
Enquiries